GlassScriptPhysician profile
Jennifer Johns Sinquefield
NPI 1972079770
$1,855.75
in general payments reported to CMS, 2019-2025
33 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,076 · 2022: $349 · 2023: $118 · 2024: $148 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $430.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $269.50 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $201.47 | 2021 | |
| Novo Nordisk INC | $143.43 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $120.72 | 2021-2024 | Veozah |
| Seagen INC. | $118.00 | 2021 | |
| Incyte Corporation | $102.94 | 2021 | |
| Amgen INC. | $79.27 | 2021 | |
| Pfizer INC. | $76.73 | 2021-2025 | |
| Abbvie INC. | $73.32 | 2021-2025 | |
| Lilly USA, LLC | $64.45 | 2021 | |
| Janssen Biotech, INC. | $54.09 | 2021 | |
| Octapharma USA, INC. | $49.97 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $49.74 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $45.29 | 2023 | |
| Csl Behring | $41.89 | 2021-2024 | Idelvion, Afstyla |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $38.12 | 2024 | Cologuard Collection Kit |
| Kite Pharma, INC. | $37.81 | 2021 | |
| Daiichi Sankyo INC. | $36.35 | 2021 | |
| Glaxosmithkline, LLC. | $22.08 | 2021 | |
| Servier Pharmaceuticals LLC | $20.26 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.86 | 2021 | |
| Dexcom, INC. | $19.75 | 2025 | Dexcom G6 Transmitter |
| Dova Pharmaceuticals | $19.15 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.78 | 2021 | |
| Boston Scientific Corporation | $17.06 | 2023 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $16.69 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.45 | 2021 | |
| Blue Earth Diagnostics | $15.41 | 2021 | |
| Kyowa Kirin, INC. | $14.98 | 2021 | |
| Genentech USA, INC. | $13.99 | 2021 | |
| Array Biopharma INC | $13.14 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.82 | 2021 | |
| Celgene Corporation | $12.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Sinquefield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.